Is radiosensitive cell line cross-sensitive to heat?: Effect of heat on two rat yolk sac tumor cell lines with different radiosensitivity

1999 ◽  
Vol 142 (2) ◽  
pp. 195-200 ◽  
Author(s):  
Norio Mitsuhashi ◽  
Mohammad Shahidul Islam ◽  
Hideyuki Sakurai ◽  
Takeo Takahashi ◽  
Osamu Murata ◽  
...  
2001 ◽  
Author(s):  
Mohammad Islam ◽  
Norio Mitsuhashi ◽  
Tetsuo Akimoto ◽  
Hideyuki Sakurai ◽  
Masatoshi Hasegawa ◽  
...  

1979 ◽  
Vol 24 (3) ◽  
pp. 341-348 ◽  
Author(s):  
Yutaka Tsukada ◽  
Nozomu Hibi ◽  
Shigeo Sakashita ◽  
Kazuhiro Abe ◽  
Hidematsu Hirai

Author(s):  
Katsuya Maebayashi ◽  
Norio Mitsuhashi ◽  
Takeo Takahashi ◽  
Hideyuki Sakurai ◽  
Hideo Niibe

1999 ◽  
Vol 147 (1-2) ◽  
pp. 199-206 ◽  
Author(s):  
Tetsuo Akimoto ◽  
Norio Mitsuhashi ◽  
Hiroko Matsumoto ◽  
Hideyuki Sakurai ◽  
Katsuya Maebayashi ◽  
...  

1992 ◽  
Vol 28 (6) ◽  
pp. 449-454 ◽  
Author(s):  
Kiyoshi Ohkawa ◽  
Takashi Hatano ◽  
Naoko Takizawa ◽  
Kazue Shinmoto ◽  
Kyosuke Yamada ◽  
...  

1993 ◽  
Vol 84 (12) ◽  
pp. 1287-1291 ◽  
Author(s):  
Norio Mitsuhashi ◽  
Takeo Takahashi ◽  
Miwako Nozaki ◽  
Hiroko Matsumoto ◽  
Hideyuki Sakurai ◽  
...  

Blood ◽  
1989 ◽  
Vol 74 (6) ◽  
pp. 2244-2251
Author(s):  
SS Kulkarni ◽  
ZM Wang ◽  
G Spitzer ◽  
M Taha ◽  
H Hamada ◽  
...  

The effectiveness of ex vivo chemotherapy with drugs, such as vincristine, etoposide, and Adriamycin (doxorubicin, Adria Labs, Columbus, OH) for elimination of residual tumor cells from human bone marrow grafts could be undermined by the presence of multidrug- resistant tumor cells in the bone marrow. Therefore, to supplement chemoseparation, we investigated whether MRK-16, a monoclonal antibody (MoAb) to the surface moiety of multidrug resistance-associated P- glycoprotein antigen, can eliminate drug-resistant tumor cells in the presence of rabbit complement (RC). Two doxorubicin (DOX)-resistant human myeloma tumor cell line, 8226/DOX40 (resistant to 4 x 10(-7) mol/L DOX) and 8226/DOX6 (6 x 10(-8) mol/L DOX) with high and low amounts of cell surface P-glycoprotein, respectively, and the drug- sensitive parent cell line 8226/S were used as tumor models in this study. Using the limiting dilution assay, we have shown that three cycles of treatment with 25 micrograms/mL of MRK-16 MoAb and a 1:4 final dilution of RC eliminated 2.90 +/- 0.10 logs of 8226/DOX40 cells and 1.94 +/- 0.18 logs of 8226/DOX6 cells. One and two cycles of treatment were less effective, eliminating 0.47 +/- 0.40 and 1.94 +/- 0.36 logs of 8226/DOX40 and 0.12 +/- 0.20 and 1.63 +/- 0.58 logs of 8226/DOX6 cells, respectively. The 8226/S cell growth was unaffected by one to three cycles of treatment. The cell kill was not impaired when the antibody plus complement treatment was carried out on a mixture of 8226/DOX40 or 8226/DOX6 cells with a ninefold excess of irradiated bone marrow mononuclear cells (MNCs). The three cycles of treatment with antibody plus complement did not adversely affect granulocyte- macrophage colony-forming unit (GM-CFU) survival in hematologically normal marrows (92.5% to 104% survival) or in myeloma patient marrows (85% to 100%). These results show that it is possible to eliminate drug- resistant myeloma tumor cell lines from the admixed human bone marrow by treatment with MRK-16 MoAb plus RC. This method could prove to be effective for elimination of other drug-resistant tumor cell lines including those of leukemia and solid tumors, and will be further useful for supplementing chemopurging, and immunopurging of bone marrow with other antitumor cell antibodies.


2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Saidu I. Ngulde ◽  
Umar K. Sandabe ◽  
Roger Abounader ◽  
Ying Zhang ◽  
Isa M. Hussaini

Cancer is a debilitating disease that is on the increase in both developed and developing countries. Anticancer drugs are often expensive, have narrow spectrum of activities, and are associated with toxicities and side effects such as myelosuppression, immunosuppression, gastrointestinal disturbance, alopecia, skin toxicity, and hepatotoxicity. Plants have been the major source of anticancer drugs both in orthodox and traditional medicine. Many of the plants claimed by the traditional medicine practitioners (TMPs) to be effective in the treatment of cancer are yet to be evaluated scientifically. In this work, five medicinal plants used by TMPs in Borno State, Nigeria, were tested against two brain tumor cell lines. Ethanol extracts of Securidaca longepedunculata, Andira inermis subsp. rooseveltii, Annona senegalensis, Carissa edulis, and Parinari polyandra were used. U87 and U231 brain tumor cell lines were used for proliferation assay, U251 cell line was used for the invasion assay in collagen V coated inserts, and U87 cell line was used for the western blot detection of cleaved Poly-ADP-Ribose-Polymerase (PARP). The result revealed that all tested extracts significantly (p<0.05) inhibited the proliferation of U87 and U231 cell lines with the respective IC50 values ranging between 8 and 20 μg/ml for S. longepedunculata and 100 and 90 μg/ml for P. polyandra. The five extracts significantly (p<0.05) inhibited the invasion of U251 cell line at the concentration of 10 μg/ml (S. longepedunculata), 20 μg/ml (A. inermis), 50 μg/ml (A. senegalensis), 50 μg/ml (C. edulis), and 50 μg/ml (P. polyandra). Securidaca longepedunculata extract induced the cleavage of PARP. It was concluded that these medicinal plants have antiproliferative and anti-invasive activities and possess good prospects as source of anticancer agents especially S. longepedunculata which induced apoptosis in U87 cell line.


Sign in / Sign up

Export Citation Format

Share Document